It not worth $5 yet. Needs to pass FDA first.
Also need to understand what $$ are attached to Ultralute.
The Hunter study for other indications could broaden scope significantly.
I reckon current price is about right for CYC without FDA, without Ultralute and without new indications.
Unlike some tech stocks which trade on extreme multiples based on blue sky, the biotechs are played more conservatively in my view because people get burnt when an ‘approval’ doesn’t eventuate or a study doesn’t show what is expected.
These risks are still there with CYC, but much less so.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.005(0.50%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | $1.00 | $215.2K | 211.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10089 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 3762 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |